Abstract:Introduction: Alzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody uptake in the brain is limited by the blood-brain barrier (BBB). Previously, we demonstrated that antibody transport across the BBB can be facilitated through interaction with the transferrin receptor (TfR), and the bispecific antibody-based PET ligands were capable of detecting Aβ aggregates via ex vivo imaging. Since tau accumulation in the brain is more closely correlated with neuronal death and cognition, we report here our strategies to prepare four F-18-labeled specifically engineered bispecific antibody probes for the selective detection of tau and Aβ aggregates to evaluate their feasibility and specificity, particularly for in vivo PET imaging. Methods: We first created and evaluated (via both in vitro and ex vivo studies) four specifically engineered bispecific antibodies, by fusion of single-chain variable fragments (scFv) of a TfR antibody with either a full-size IgG antibody of Aβ or tau or with their respective scFv. Using [18F]SFB as the prosthetic group, all four 18F-labeled bispecific antibody probes were then prepared by conjugation of antibody and [18F]SFB in acetonitrile/0.1 M borate buffer solution (final pH ~ 8.5) with an incubation of 20 min at room temperature, followed by purification on a PD MiniTrap G-25 size exclusion gravity column. Results: Based on both in vitro and ex vivo evaluation, the bispecific antibodies displayed much higher brain concentrations than the unmodified antibody, supporting our subsequent F18-radiolabeling. [18F]SFB was produced in high yields in 60 min (decay-corrected radiochemical yield (RCY) 46.7 ± 5.4) with radiochemical purities of >95%, confirmed by analytical high performance liquid chromatography (HPLC) and radio-TLC. Conjugation of [18F]SFB and bispecific antibodies showed a 65%-83% conversion efficiency with radiochemical purities of 95%-99% by radio-TLC. Conclusions: We successfully labeled four novel and specifically engineered bispecific antibodies with [18F]SFB under mild conditions with a high RCY and purities. This study provides strategies to create brain-penetrable F-18 radiolabeled antibody probes for the selective detection of tau and Aβ aggregates in the brain of transgenic AD mice via in vivo PET imaging.

Image-Guided Development of Heterocyclic Sulfoxides as Ligands for Tau Neurofibrillary Tangles: From First-in-Man to Second-Generation Ligands

Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer's disease tauopathies

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

Synthesis and Preclinical Evaluation of Diarylamine Derivative As Tau-PET Radiotracer for Alzheimer’s Disease

Synthesis and Preclinical Evaluation of 2-(4-[18f]fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([18F]FPND-4): an Aza-Fused Tricyclic Derivative As Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging.

Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Recent Development in Selective Tau Tracers for PET Imaging in the Brain

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

In vitro evaluation of [3H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies

Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives As Potential Tau Imaging Agents.

Synthesis and Bioevaluation of 2-Styrylquinoxaline Derivatives As Tau-PET Tracers.

Preliminary mechanistic insights of a brain-penetrant microtubule imaging PET ligand in a tau-knockout mouse model

Synthesis and Preclinical Evaluation of 2-(4-[ 18 F]Fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([ 18 F]FPND-4): An Aza-Fused Tricyclic Derivative as Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging

Identification of novel tau positron emission tomography tracers for chronic traumatic encephalopathy by comprehensive in silico screening and molecular dynamics simulation

Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort

Improved Preparation and Chemical Kinetics on Fully Automated Synthesis of [ 18 F]-THK523, a PET Imaging Probe for Tau Pathologies

Development of Novel 18F-Labeled PET Tracers for Imaging TSPO with Insensitivity to Rs6971 Polymorphism

Development of A Novel Radioiodinated Compound for Amyloid and Tau Deposition Imaging in Alzheimer's Disease and Tauopathy Mouse Models

Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates